Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

RCT2100

Phase 2Small molecule

RReCode Therapeutics

RCT2100 is one of 42 small molecule programs targeting Cystic Fibrosis. It is currently in Phase 2.

1

Indications

1

Total Trials

1

Active Trials

41

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cystic FibrosisActive, not recruiting

Cystic FibrosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

105 competitors in Cystic Fibrosis

#DrugCompanyPhaseTrials

Ibsrela

Biaxin

Avelox

Lamprene

HSK31858

Haisco Pharmaceutical Group Co., Ltd.

Sirturo

ELX/TEZ/IVA

Vertex Pharmaceuticals

Trikafta

NNottingham University Hospitals NHS Trust

VNZ/TEZ/D-IVA

Vertex Pharmaceuticals

VX-121/TEZ/D-IVA

Vertex Pharmaceuticals

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cystic Fibrosis1 trial

A Phase 1/2, Multicenter Study Evaluating the Safety, Tolerability, and Biodistribution of RCT2100 With Single-Ascending Doses in Healthy Participants and Multiple-Ascending Doses and Proof-of-Concept in Participants With Cystic Fibrosis

Active, not recruiting·RReCode Therapeutics·Phase 2·NCT06237335·128 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RCT2100. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RCT2100 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RCT2100. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ReCode Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: RReCode Therapeutics

Related News